Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.

Autor: Zhang J; Department of Dermatology, University Medical Center Groningen, Groningen, The Netherlands., Boesjes CM; National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands., Loman L; Department of Dermatology, University Medical Center Groningen, Groningen, The Netherlands., Kamphuis E; Department of Dermatology, University Medical Center Groningen, Groningen, The Netherlands., Romeijn MLE; Department of Dermatology, University Medical Center Groningen, Groningen, The Netherlands., Spekhorst LS; National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands., Haeck I; Department of Dermatology, Reinier de Graaf Hospital, Delft, The Netherlands., van der Gang LF; National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands., Dekkers CC; National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands., van der Rijst LP; National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands., Oosting AJ; Department of Dermatology, Spaarne Gasthuis, Hoofddorp, The Netherlands., van Lumig P; Department of Dermatology, University Medical Center Maastricht, Maastricht, The Netherlands., van Lynden-van Nes AMT; Department of Dermatology, Meander Medical Center, Amersfoort, The Netherlands., Tupker RA; Department of Dermatology, St Antonius Hospital, Nieuwegein, The Netherlands., Nijssen A; Department of Dermatology, Haga Hospital, Den Haag, The Netherlands., Flinterman A; Department of Dermatology, Diakonessenhuis, Utrecht, The Netherlands., Politiek K; Department of Dermatology, Medical Center Leeuwarden, Leeuwarden, The Netherlands., Touwslager WRH; Department of Dermatology, Catharina Hospital, Eindhoven, The Netherlands., Christoffers WA; Department of Dermatology, Isala Hospital, Zwolle, The Netherlands., Stewart SM; Department of Dermatology, IJsselland Hospital, Capelle aan den IJssel, The Netherlands., Kamsteeg M; Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands., de Graaf M; National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands., de Bruin-Weller MS; National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands., Schuttelaar MA; Department of Dermatology, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: m.l.a.schuttelaar@umcg.nl.
Jazyk: angličtina
Zdroj: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Aug; Vol. 91 (2), pp. 300-311. Date of Electronic Publication: 2024 Apr 21.
DOI: 10.1016/j.jaad.2024.04.026
Abstrakt: Background: Long-term daily practice data on patient-reported benefits of dupilumab for atopic dermatitis (AD) remains limited.
Objective: To evaluate patient-reported outcome measures (PROMs) and the safety of dupilumab in patients with moderate-to-severe AD over a follow-up period of up to 5 years.
Methods: Data were extracted from the prospective, multicenter BioDay registry (October 2017-2022) of patients with moderate-to-severe AD treated with dupilumab in daily practice.
Results: In total 1223 patients, 1108 adults and 115 pediatric patients were included. After ≥1 year of treatment, mean Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), Numeric rating scale (NRS)-pruritus ranged between 7.8 and 8.7, 3.5 and 4.2, and 2.9 and 3.1 in adults, respectively, whilst these patient-reported outcome measures (PROMs) ranged between 8.9 and 10.9, 4.4 and 6.4, and 3.0 and 3.7 in pediatric patients, respectively. At follow-up, overall work impairment decreased from 40.1% to 16.3% to 13.3% in adults. Furthermore, class I obesity and itch-dominant patients generally had less favorable treatment response. Of all patients, 66.8% reported ≥1 adverse event, with conjunctivitis being the most common (33.7%).
Limitations: The overall percentage of missing values for selected PROMs was 26% in adults and 46% in pediatric patients.
Conclusion: In addition to favorable safety, dupilumab has demonstrated sustained effectiveness across various PROMs, underscoring the treatment benefits from patients' perspectives.
Competing Interests: Conflicts of interest C.M. Boesjes is a speaker for AbbVie and Eli Lilly. L.S. Spekhorst is a speaker for AbbVie. I.M. Haeck is a consultant, advisory board member, and/or speaker for Sanofi and Regeneron Pharmaceuticals, LEO Pharma, AbbVie, Janssen, and Eli Lilly. L.F. van der Gang is a speaker for AbbVie. L.P. van der Rijst is a speaker for AbbVie. R.A. Tupker is an advisory board member of Leo Pharma, Eli Lilly, and Novartis. K.Politiek was an advisory board member and/or speaker for AbbVie, LEO Pharma, Novartis, and Sanofi. W. Touwslager is an advisor, consultant, and speaker for Sanofi, Leo Pharma, AbbVie, and Novartis. WA Christoffers is an advisory board member of Leo Pharma. M. de Graaf is a consultant, advisory board member, and/or speaker for AbbVie, Almiral, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, and Sanofi. M.S. de Bruin-Weller is a consultant, advisory board member, and/or speaker for AbbVie, Almirall, Aslan, Amgen, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, and Sanofi. M.L.A. Schuttelaar is an advisor, consultant, speaker, and/or investigator for AbbVie, Pfizer, LEO Pharma, Regeneron, Sanofi, Eli Lilly, and Galderma. She has received grants from Regeneron, Sanofi, Novartis, and Pfizer.
(Copyright © 2024 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: